TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25623462

Group type: EXPERIMENTAL
Intervention: Microecologic treatment combined enteral nutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Probiotics only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous nutrition
Number of subjects: 60
Study: 22827780

Group type: EXPERIMENTAL
Intervention: Soy nuts (35 g/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Textured soy protein (TSP) (35 g/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 19208678

Group type: EXPERIMENTAL
Intervention: PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (BEV/PPV group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PPV only (PPV group)
Number of subjects: 20
Study: 17205251

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% in 50 ml of saline 0.9% (Group B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% in 40 ml of saline 0.9% (Group C)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%) (Group A)
Number of subjects: 46
Study: 15140341

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7 days
Number of subjects: 581

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg once daily for 10 days
Number of subjects: 581
Study: 11383931

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9702472

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose ANP (2.5 pmol kg‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose ANP (5.0 pmol kg‐1 min‐1)
Number of subjects: 8
Study: 7980309

Group type: EXPERIMENTAL
Intervention: Condom use for 6 months
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Local ablative therapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Condom use after ablative therapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Observation (Control Group 1)
Number of subjects: 222
Study: 2967742

Group type: EXPERIMENTAL
Intervention: Isradipine (15 mg/day, 5 mg t.i.d.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day, 80 mg t.i.d.)
Number of subjects: 19
Study: 31709984

Group type: EXPERIMENTAL
Intervention: Stratified medical therapy guided by invasive coronary function testing
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 151
Study: 29911878

Group type: EXPERIMENTAL
Intervention: Social Competence Intervention for Adolescents (SCI-A)
Number of subjects: 274

Group type: COMPARATOR
Intervention: business-as-usual (BAU) practices
Number of subjects: 274
Study: 28590767

Group type: EXPERIMENTAL
Intervention: Biodanza
Number of subjects: 121
Study: 25974723

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement containing whey (LNS/w)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement containing soy (LNS/s)
Number of subjects: 282

Group type: COMPARATOR
Intervention: No lipid-based nutrient supplement (Control)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: CYP2B6 516 G>T polymorphism
Number of subjects: 282
Study: 23758902

Group type: EXPERIMENTAL
Intervention: 20-min motor electrical stimulation (ES)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40-min motor electrical stimulation (ES)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 60-min motor electrical stimulation (ES)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control for peripheral effects (M-waves)
Number of subjects: 14
Study: 20807859

Group type: EXPERIMENTAL
Intervention: Popliteus muscle activation during squats
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Squat exercise
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Popliteus muscle-tendon unit exercise
Number of subjects: 17
Study: 18445174

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 147
Study: 16564934

Group type: EXPERIMENTAL
Intervention: AST-120 (Kremezin) 0.9 g, 2.1 g, or 3.0 g, administered 3 times daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered 3 times daily for 12 weeks
Number of subjects: 0
Study: 14601338

Group type: EXPERIMENTAL
Intervention: Risk communication package containing visual material
Number of subjects: 1890

Group type: COMPARATOR
Intervention: Normal practice (Control)
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Risk communication package
Number of subjects: 1890
Study: 10783019

Group type: EXPERIMENTAL
Intervention: Positive influenza A enzyme immunoassay (EIA) test
Number of subjects: 56

Group type: COMPARATOR
Intervention: Negative influenza A enzyme immunoassay (EIA) test
Number of subjects: 56

Group type: COMPARATOR
Intervention: No rapid diagnosis
Number of subjects: 56
Study: 8793432

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 120
Study: 1536441

Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (IPC group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intramuscular buprenorphine (opioid group)
Number of subjects: 26
Study: 6540222

Group type: EXPERIMENTAL
Intervention: Corticosteroids and droperidol
Number of subjects: 0
Study: 31858963

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo (advanced to tofacitinib at month 3 or 6)
Number of subjects: 797
Study: 30597768

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 30382909

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 248
Study: 27495978

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard clinic-based education
Number of subjects: 116
Study: 24155184

Group type: EXPERIMENTAL
Intervention: Adlerian Parental Counseling (APC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No intervention (non-APC group)
Number of subjects: 114
Study: 22644005

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 88
Study: 20566677

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 17387123

Group type: EXPERIMENTAL
Intervention: Home-based medication review by a pharmacist
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 136
Study: 16304312

Group type: EXPERIMENTAL
Intervention: EBUS‐TBB
Number of subjects: 293

Group type: COMPARATOR
Intervention: TBB
Number of subjects: 293
Study: 12528325

Group type: EXPERIMENTAL
Intervention: Bovine colostrum milk preparation (42 g per day for 2 days preoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9719976

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia (STA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Retro/peribulbar anesthesia (RBA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: All techniques (RBA, STA, TA)
Number of subjects: 66
Study: 8124121

Group type: EXPERIMENTAL
Intervention: Nurse led programme using a family centred approach with follow up according to degree of risk
Number of subjects: 12472

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12472

Group type: EXPERIMENTAL
Intervention: Nurse led programme
Number of subjects: 12472
Study: 2527760

Group type: EXPERIMENTAL
Intervention: Oral thymoxamine 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral thymoxamine 80 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study: 202985

Group type: EXPERIMENTAL
Intervention: Viloxazine 200 mg daily for 3 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Viloxazine 300 mg daily for 3 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Matching blanks (control)
Number of subjects: 23
Study: 31733098

Group type: EXPERIMENTAL
Intervention: Liability to ADHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smoking initiation
Number of subjects: 0
Study: 31262551

Group type: EXPERIMENTAL
Intervention: Face-to-face treatment (FtF)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Chat-based treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waiting list control (WL)
Number of subjects: 73
Study: 28651927

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus evofosfamide (300 mg/m2 intravenously for 30-60 min on days 1 and 8 of every 21-day cycle for up to six cycles)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Doxorubicin alone (75 mg/m2 via bolus injection or continuous intravenous infusion for 6-96 h on day 1 of every 21-day cycle for up to six cycles)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus evofosfamide
Number of subjects: 640

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 640
Study: 25465885

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training toward non-threat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training toward threat
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contingency condition
Number of subjects: 0
Study: 23238034

Group type: EXPERIMENTAL
Intervention: 4 cups of coffee/day for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coffee abstinence
Number of subjects: 40
Study: 21814869

Group type: EXPERIMENTAL
Intervention: Gatekeeper training plus brief behavioral rehearsal (role play practice)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Gatekeeper training as usual
Number of subjects: 147
Study: 19344047

Group type: EXPERIMENTAL
Intervention: KADIAN q24h dosing
Number of subjects: 1428

Group type: COMPARATOR
Intervention: KADIAN q12h dosing
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: KADIAN q12h dosing after switch
Number of subjects: 1428
Study: 16731460

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined endpoint of hospitalization for heart failure or death
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: New-onset AF in patients with baseline sinus rhythm
Number of subjects: 102
Study: 15341360

Group type: EXPERIMENTAL
Intervention: Tongue scraper
Number of subjects: 10

Group type: COMPARATOR
Intervention: Soft-bristle toothbrush
Number of subjects: 10
Study: 11144399

Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg once-daily
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg b.i.d.
Number of subjects: 752

Group type: COMPARATOR
Intervention: Amoxicillin/CA 13.3 mg/kg t.i.d.
Number of subjects: 752
Study: 9134599

Group type: EXPERIMENTAL
Intervention: BCG therapy (120 mg in 50 mL saline, 5 x 10^7 viable organisms), weekly for 6 weeks after TUR
Number of subjects: 69

Group type: COMPARATOR
Intervention: TUR alone (control)
Number of subjects: 69
Study: 8362997

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus incentives
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health risk assessment and risk factor education
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 28
Study: 3521523

Group type: EXPERIMENTAL
Intervention: Amiloride‐hydrochlorothiazide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Triamterene‐hydrochlorothiazide
Number of subjects: 17
Study: 31362537

Group type: EXPERIMENTAL
Intervention: MBB coaching (treatment)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (no coaching)
Number of subjects: 195
Study: 29338723

Group type: EXPERIMENTAL
Intervention: MISP-NZ intervention (25 months duration) including training in recognition of suicide risk factors, workshops on mental health issues, community-based interventions, and distribution of print material and web-based resources.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Practice as usual (control group)
Number of subjects: 8
Study: 26762175

Group type: EXPERIMENTAL
Intervention: MIS group (mini-midvastus approach)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional group (medial parapatellar approach)
Number of subjects: 69
Study: 24449012

Group type: COMPARATOR
Intervention: Eyes Open
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyes Closed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertically Oscillating Radial Flow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smooth Radial Flow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillating Displays
Number of subjects: 0
Study: 22285969

Group type: EXPERIMENTAL
Intervention: CPVI
Number of subjects: 156

Group type: COMPARATOR
Intervention: CPVI+RL
Number of subjects: 156

Group type: COMPARATOR
Intervention: CPVI+PostBox
Number of subjects: 156
Study: 21053789

Group type: EXPERIMENTAL
Intervention: Integrated dementia intervention (cognitive stimulation training, exercise, music, art, and horticultural therapy)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 38
Study: 17701157

Group type: EXPERIMENTAL
Intervention: Total oestradiol (highest vs lowest quintile)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Free oestradiol (highest vs lowest quintile)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Total testosterone (highest vs lowest quintile)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Free testosterone (highest vs lowest quintile)
Number of subjects: 718
Study: 15480814

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day (escalating to 10 mg after 1 month) and vitamin E 1,000 IU/day
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 12078939

Group type: EXPERIMENTAL
Intervention: Non-tapering prednisolone (40 mg/day for 8 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tapering prednisolone (40 mg tapering by 5 mg/day for 8 days)
Number of subjects: 26
Study: 9698776

Group type: EXPERIMENTAL
Intervention: Sublingual propranolol (40 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Peroral propranolol (40 mg)
Number of subjects: 14
Study: 7608665

Group type: EXPERIMENTAL
Intervention: Apomorphine (mean dose 3.4 mg, range 0.8-6.0 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2930672

Group type: EXPERIMENTAL
Intervention: Halothane 1.5%
Number of subjects: 6

Group type: COMPARATOR
Intervention: Thiopentone (Control)
Number of subjects: 6
Study: 326433

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (800 microng intranasally for 1 week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31253718

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 3994

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3994
Study: 30629187

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in HIV-infected adults
Number of subjects: 389
Study: 28212353

Group type: EXPERIMENTAL
Intervention: 5 g PGX granules (PGXG)
Number of subjects: 118
Study: 26306332

Group type: EXPERIMENTAL
Intervention: Florfenicol at 10 mg/kg (medicated feed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unmedicated feed (0 mg/kg)
Number of subjects: 30
Study: 23899886

Group type: EXPERIMENTAL
Intervention: Combined hearing aid or sound generator with betahistine dihydrochloride (2HCl)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Betahistine dihydrochloride (2HCl)
Number of subjects: 21
Study: 21826593

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 plus Yiqi zhuyu decoction (YZD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: FOLFOX-4 plus placebo
Number of subjects: 120
Study: 19295645

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g) + Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tinidazole (2 g) + Placebo
Number of subjects: 64
Study: 16960024

Group type: EXPERIMENTAL
Intervention: Family-style meals for 6 months
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Family-style meals
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual individual preplating services
Number of subjects: 178
Study: 15289281

Group type: EXPERIMENTAL
Intervention: Quality improvement interventions aimed at increasing guideline‐concordant depression care
Number of subjects: 1356
Study: 11208725

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 50 microg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 500 microg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 50 microg bolus followed by continuous infusion of 50 microg/h
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 250 microg/h continuous infusion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Repeated 50 microg injections of octreotide after an initial bolus
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo bolus and continuous octreotide infusion (50 microg/h)
Number of subjects: 68
Study: 9782912

Group type: EXPERIMENTAL
Intervention: Nursing diagnosis course (experimental group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no nursing diagnosis course)
Number of subjects: 37
Study: 7929833

Group type: EXPERIMENTAL
Intervention: Adenosine infusion during fasting (n = 6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adenosine infusion during euglycemic insulin clamp (n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control forearm during euglycemic insulin clamp
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adenosine infusion in one forearm during euglycemic insulin clamp
Number of subjects: 14
Study: 3129445

Group type: EXPERIMENTAL
Intervention: Naloxone (0.08 mg/kg BW, iv)
Number of subjects: 17

Group type: COMPARATOR
Intervention: GnRH (50 micrograms, iv)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31891330

Group type: EXPERIMENTAL
Intervention: Steno REACH Certificate Course in Clinical Diabetes Care (SRCC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 30297240

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens (folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, and irinotecan, with or without cetuximab)
Number of subjects: 1543
Study: 28396887

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) placed under a coronally advanced flap (CAF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG) placed under a coronally advanced flap (CAF)
Number of subjects: 12
Study: 26269371

Group type: EXPERIMENTAL
Intervention: Behavioral intervention emphasizing spices and herbs (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-directed control group (n = 20)
Number of subjects: 40
Study: 24339703

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20370961

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine (SGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine (SGA)
Number of subjects: 0
Study: 19057823

Group type: EXPERIMENTAL
Intervention: DTP/Hib-BM
Number of subjects: 1000

Group type: COMPARATOR
Intervention: DTP/Hib-GSK
Number of subjects: 1000
Study: 16844625

Group type: EXPERIMENTAL
Intervention: Plasma levels of TNF‐alpha rose more than 20 pg/mL during and after standard CPB in 13 patients (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma levels of TNF‐alpha were less than 20 pg/mL in the remaining 7 patients (group 2)
Number of subjects: 20
Study: 12727963

Group type: EXPERIMENTAL
Intervention: Low-dose GH (Genotropin 0.4 mg/d) for 8 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10969256

Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin (BTA) injection plus occupational therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occupational therapy alone
Number of subjects: 30
Study: 8853138

Group type: EXPERIMENTAL
Intervention: Coronary splinting
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 2003499

Group type: EXPERIMENTAL
Intervention: Medication profile review by a clinical pharmacist
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (no medication profile review)
Number of subjects: 572
Study: 6385355

Group type: EXPERIMENTAL
Intervention: Pilocarpine 2 per cent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adrenaline 1 per cent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guanethidine 3 per cent plus adrenaline 0.5 per cent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Timolol 0.25 per cent
Number of subjects: 12
Study: 31587950

Group type: COMPARATOR
Intervention: Conventional microcatheter PAE (cPAE)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Balloon occlusion prostatic artery embolization (bPAE)
Number of subjects: 89
Study: 30249191

Group type: EXPERIMENTAL
Intervention: Nocebo-education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention Control Group (ACG)
Number of subjects: 100
Study: 26657482

Group type: EXPERIMENTAL
Intervention: Spray application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cotton swab application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rinsing with fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Number of subjects: 21
Study: 24639426

Group type: EXPERIMENTAL
Intervention: dalcetrapib 600 mg/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 300